A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
COVID 19 BY NAA
Test CodeLAB7323
CPT Codes
87635
Includes
Detection of COVID-19 viral RNA
Preferred Specimen
Request swab from lab.
Patient Preparation
To collect a nasal swab sample, cafefully insert the swab into the nostril exhibiting the most visible drainage or the nostril that is most congested if drainage is not visible. Usine gentle rotation, push the swab until resistance is met at the level of the turbinates (less than one ince into the nostril). Rotate the swab several times against the nasal wall then slowly remove from the nostril. Using the same swab, repeat sample collection in the other nostril.
Other Acceptable Specimens
Sterile Foam Tipped Swab

Transport Temperature
Room Temperature
Specimen Stability
- 15-30°C up to 1 hour
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Samples greater than 1 hour from collection will not be accepted for testing.
Methodology
Isothermal Nucleic Acid Amplification (NAAT)
Setup Schedule
DAILY, as received
Report Available
STAT: <60 minutes
Reference Range
Negative
Clinical Significance
Negative results do not preclude SARS-Co-V-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.
This test has not been FDA cleared or approved. This test has been authorized by the FDA under an Emergency Use Authorization (EUA). This test has been authorized only for detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for the detection of SARS-Co-V2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
This test has not been FDA cleared or approved. This test has been authorized by the FDA under an Emergency Use Authorization (EUA). This test has been authorized only for detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for the detection of SARS-Co-V2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Performing Laboratory
Mount Sinai Hospital
Holy Cross Hospital